All In MedTech

Device Trial Radar · NCT02032238

Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema

Last checked: Nov 20, 2026Latest source record: Aug 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

12

Actual

Start

Mar 2013

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Lead sponsor
OD-OS GmbHNot on our public-company list
Sponsor type
Industry
First posted
Jan 9, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Asses efficacy of navigated laser in reducing the number of anti-VEGF injections as a prospective study using Bevacizumab.

Conditions

  • Clinically Significant Macular Edema

Interventions

  • laser photocoagulationDevice

    Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Eyes That Received RetreatmentTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye and Ear Infirmary

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.